Tag: Therapeutics

Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating non-clinical proof of concept for SolidT cells co-administered with therapeutic antibodies. Cambridge, MA, USA – WEBWIRE – Tuesday, April 9, 2024 Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the presentation of pre-clinical data at the annual meeting of the American Association for Cancer Research demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed, and establish immune memory to eliminate secondary tumors. The presentation is entitled ... Read more

 Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT’s cutting-edge technologies into the market. Dr Tulip brings decades of invaluable experience in developing and successfully commercializing imaging agents to MVT. With a notable track record of contributing to the regulatory approval of 15 new chemical entities and expanding indications, Dr Tulip’s expertise aligns seamlessly with MVT’s mission to ... Read more

MELBOURNE, Jan 16, 2024 – (ACN Newswire) – Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company’s PRT120 oral therapy for peanut allergy. “SPRIM brings valuable expertise, capabilities and an international investment network to Prota’s technology and clinical program,” said Prota Executive Chairman Kelly Constable. “This partnership and funding will accelerate Prota’s drug development ... Read more

HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund. Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company’s robust pipeline. HighTide’s lead candidate HTD1801, is a novel multifunctional molecule, being developed for the treatment of patients suffering from complex metabolic ... Read more

 Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022. Dr. Vankayalapati said of the data, “We are excited to have found a way to promote degradation in neuroendocrine prostate cancer cells and hope that this will ... Read more